Literature DB >> 35751791

Advancement in CRISPR/Cas9 Technology to Better Understand and Treat Neurological Disorders.

Aishika Datta1, Deepaneeta Sarmah1, Harpreet Kaur1, Antra Chaudhary1, Namrata Vadak1, Anupom Borah2, Sudhir Shah3, Xin Wang4, Pallab Bhattacharya5.   

Abstract

Neurological disorders have complicated pathophysiology that may involve several genetic mutations. Conventional treatment has limitations as they only treat apparent symptoms. Although, personalized medicine is emerging as a promising neuro-intervention, lack of precision is the major pitfall. Clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system is evolving as a technological platform that may overcome the therapeutic limitations towards precision medicine. In the future, targeting genes in neurological disorders may be the mainstay of modern therapy. The present review on CRISPR/Cas9 and its application in various neurological disorders may provide a platform for its future clinical relevance towards developing precise and personalized medicine.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRISPR/Cas; Genome editing tools; Neurological disorders; TALENs; ZFNs

Year:  2022        PMID： 35751791     DOI： 10.1007/s10571-022-01242-3

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN： 0272-4340            Impact factor:   5.046


  70 in total

Review 1.  The CRISPR/Cas9 system for plant genome editing and beyond.

Authors:  Luisa Bortesi; Rainer Fischer
Journal:  Biotechnol Adv       Date:  2014-12-20       Impact factor: 14.227

2.  Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.

Authors:  Ranjan Batra; David A Nelles; Elaine Pirie; Steven M Blue; Ryan J Marina; Harrison Wang; Isaac A Chaim; James D Thomas; Nigel Zhang; Vu Nguyen; Stefan Aigner; Sebastian Markmiller; Guangbin Xia; Kevin D Corbett; Maurice S Swanson; Gene W Yeo
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

3.  Identification of preexisting adaptive immunity to Cas9 proteins in humans.

Authors:  Carsten T Charlesworth; Priyanka S Deshpande; Daniel P Dever; Joab Camarena; Viktor T Lemgart; M Kyle Cromer; Christopher A Vakulskas; Michael A Collingwood; Liyang Zhang; Nicole M Bode; Mark A Behlke; Beruh Dejene; Brandon Cieniewicz; Rosa Romano; Benjamin J Lesch; Natalia Gomez-Ospina; Sruthi Mantri; Mara Pavel-Dinu; Kenneth I Weinberg; Matthew H Porteus
Journal:  Nat Med       Date:  2019-01-28       Impact factor: 53.440

4.  Cut site selection by the two nuclease domains of the Cas9 RNA-guided endonuclease.

Authors:  Hongfan Chen; Jihoon Choi; Scott Bailey
Journal:  J Biol Chem       Date:  2014-03-14       Impact factor: 5.157

5.  Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.

Authors:  Leonela Amoasii; Chengzu Long; Hui Li; Alex A Mireault; John M Shelton; Efrain Sanchez-Ortiz; John R McAnally; Samadrita Bhattacharyya; Florian Schmidt; Dirk Grimm; Stephen D Hauschka; Rhonda Bassel-Duby; Eric N Olson
Journal:  Sci Transl Med       Date:  2017-11-29       Impact factor: 17.956

6.  The widespread IS200/IS605 transposon family encodes diverse programmable RNA-guided endonucleases.

Authors:  Han Altae-Tran; Soumya Kannan; F Esra Demircioglu; Rachel Oshiro; Suchita P Nety; Luke J McKay; Mensur Dlakić; William P Inskeep; Kira S Makarova; Rhiannon K Macrae; Eugene V Koonin; Feng Zhang
Journal:  Science       Date:  2021-09-09       Impact factor: 47.728

7.  Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis.

Authors:  Lasse Brandt; Tom Bschor; Jonathan Henssler; Martin Müller; Alkomiet Hasan; Andreas Heinz; Stefan Gutwinski
Journal:  Front Psychiatry       Date:  2020-09-29       Impact factor: 4.157

Review 8.  Classification and evolution of type II CRISPR-Cas systems.

Authors:  Krzysztof Chylinski; Kira S Makarova; Emmanuelle Charpentier; Eugene V Koonin
Journal:  Nucleic Acids Res       Date:  2014-04-11       Impact factor: 16.971

9.  Measurement of the cosmic ray proton spectrum from 40 GeV to 100 TeV with the DAMPE satellite.

Authors:  Q An; R Asfandiyarov; P Azzarello; P Bernardini; X J Bi; M S Cai; J Chang; D Y Chen; H F Chen; J L Chen; W Chen; M Y Cui; T S Cui; H T Dai; A D'Amone; A De Benedittis; I De Mitri; M Di Santo; M Ding; T K Dong; Y F Dong; Z X Dong; G Donvito; D Droz; J L Duan; K K Duan; D D'Urso; R R Fan; Y Z Fan; F Fang; C Q Feng; L Feng; P Fusco; V Gallo; F J Gan; M Gao; F Gargano; K Gong; Y Z Gong; D Y Guo; J H Guo; X L Guo; S X Han; Y M Hu; G S Huang; X Y Huang; Y Y Huang; M Ionica; W Jiang; X Jin; J Kong; S J Lei; S Li; W L Li; X Li; X Q Li; Y Li; Y F Liang; Y M Liang; N H Liao; C M Liu; H Liu; J Liu; S B Liu; W Q Liu; Y Liu; F Loparco; C N Luo; M Ma; P X Ma; S Y Ma; T Ma; X Y Ma; G Marsella; M N Mazziotta; D Mo; X Y Niu; X Pan; W X Peng; X Y Peng; R Qiao; J N Rao; M M Salinas; G Z Shang; W H Shen; Z Q Shen; Z T Shen; J X Song; H Su; M Su; Z Y Sun; A Surdo; X J Teng; A Tykhonov; S Vitillo; C Wang; H Wang; H Y Wang; J Z Wang; L G Wang; Q Wang; S Wang; X H Wang; X L Wang; Y F Wang; Y P Wang; Y Z Wang; Z M Wang; D M Wei; J J Wei; Y F Wei; S C Wen; D Wu; J Wu; L B Wu; S S Wu; X Wu; K Xi; Z Q Xia; H T Xu; Z H Xu; Z L Xu; Z Z Xu; G F Xue; H B Yang; P Yang; Y Q Yang; Z L Yang; H J Yao; Y H Yu; Q Yuan; C Yue; J J Zang; F Zhang; J Y Zhang; J Z Zhang; P F Zhang; S X Zhang; W Z Zhang; Y Zhang; Y J Zhang; Y L Zhang; Y P Zhang; Y Q Zhang; Z Zhang; Z Y Zhang; H Zhao; H Y Zhao; X F Zhao; C Y Zhou; Y Zhou; X Zhu; Y Zhu; S Zimmer
Journal:  Sci Adv       Date:  2019-09-27       Impact factor: 14.136

10.  In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy.

Authors:  Gaia Colasante; Yichen Qiu; Luca Massimino; Claudia Di Berardino; Jonathan H Cornford; Albert Snowball; Mikail Weston; Steffan P Jones; Serena Giannelli; Andreas Lieb; Stephanie Schorge; Dimitri M Kullmann; Vania Broccoli; Gabriele Lignani
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.